Newly available: WHO HIV PrEP Implementation Tool Mobile App

World Health Organization, August 1, 2018

The WHO PrEP Implementation Tool App for Health Workers App is now available.

On-the-go access to the following modules from the WHO PrEP Implementation Tool:

  • Clinical: for clinicians, including physicians, nurses and clinical officers
  • Counsellors: for staff who counsel people as they consider or start taking PrEP, and support them in coping with side effects and adherence strategies
  • Pharmacists: for pharmacists and people working in pharmacies; to provide information on the medicines used in PrEP as well as storage conditions
  • Testing providers: for people who provide testing services at PrEP sites and laboratories
  • PrEP users: for people taking PrEP and people interested in taking PrEP to reduce their risk of acquiring HIV; to support them in their choice and use of PrEP.

For more information and to download app, click here 

You can also visit these two websites:

Two cases of multi-drug resistant gonorrhoea recently detected in Australia: media release

Professor Brendan Murphy, Commonwealth Chief Medical Officer, Australian Government Department of Health 

17 April 2018

Two cases of multi-drug resistant gonorrhoea have been recently detected in Australia. One case was diagnosed in Western Australia and a second case diagnosed in Queensland. 

Multi-drug resistant strains can be difficult to treat and it is important to prevent further spread.

Evidence suggests that one of the Australian cases acquired their infection in Southeast Asia.

The situation is being closely monitored by public health authorities.

Police, families not told of sexual assault reports by mental health patients [Report]

The Age, 29 March 2018

Sexual assault claims made by mental health patients are not being reported to police or even the alleged victims’ families in most cases, a scathing report has revealed.

Families are told of allegations in only a quarter of cases, while police reports are made only 40 per cent of the time, leaving alleged victims at risk of further abuse.

HIV PrEP available on PBS in Australia from 1 April / Links to Clinical Resources

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), 21 March 2018

ASHM congratulates the Federal Health Minister, the Hon. Greg Hunt’s announcement of a landmark in HIV prevention to approve HIV-prevention drugs – tenofovir with emtricitabine, known as PrEP – on the Pharmaceutical Benefits Scheme from 1 April, thereby providing broader access for any doctor or general practitioner to be able prescribe PrEP to an Australian resident who holds a current Medicare card.

“The public health benefits are clear, undeniable and transformative benefiting individuals at medium- to high-risk of HIV infection and towards driving a substantial reduction in HIV transmissions in Australia,” said ASHM President, Associate Professor Bloch.

Access Links to Clinical Resources supporting the HIV workforce

  • The definitions of risk for HIV, guidelines and procedures for the appropriate administration and monitoring of PrEP can be found here: ASHM HIV pre-exposure prophylaxis: clinical guidelines
  • The Australian Federation of AIDS Organisations (AFAO) and ASHM have produced a PrEP Fact Sheet to assist PrEP users and people with an interest in using PrEP to understand what subsidised access to PrEP through the PBS means. Access the factsheet here
  • ASHM continues to support the workforce to ensure access to PrEP and best practice in guidelines, training and resources. Access information here
  • The Pharmaceutical Society of Australia has a range of training to support pharmacists in preparing for PrEP on the PBS: www.psa.org.au

 

The updated 2017 ASHM HIV pre-exposure prophylaxis (PrEP) Guidelines

Journal of Virus Eradication, 2017; 3: 168–184

Daily use of co-formulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. 

These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine‘s (ASHM) PrEP Guidelines are an updated adaptation of the 2014 US Centers for Disease Control‘s PrEP guidelines and are designed to:

    • Support the prescription of PrEP using forms of coformulated tenofovir and emtricitabine that have been registered in Australia by the Therapeutic Goods Administration and other bioequivalent generic drugs that are available in Australia through self-importation, private prescription or Australian PrEP clinical trials
    • Assist clinicians in the evaluation of patients who are seeking PrEP
    • Assist clinicians in commencing and monitoring patients on PrEP including PrEP dosing schedules, management of side-effects and toxicity, use of PrEP in pregnancy and in chronic hepatitis B infection and how to cease PrEP

Daily PrEP with co-formulated tenofovir and emtricitabine, used continuously or for shorter periods of time, is recommended in these guidelines as a key HIV-prevention option for men who have sex with men (MSM), transgender men and women, heterosexual men and women, and people who inject drugs (PWID) at substantial risk of HIV acquisition.

Managing Chronic Hepatitis B – Advice for GPs (SHINE SA video)

SHINE SA, July 2017

Today, July 28th, is World Hepatitis Day.

There are no ‘healthy carriers’ of hepatitis B!

SA Health & SHINE SA are promoting a 6-minute video providing advice for general practitioners in diagnosing, managing and contact tracing patients with chronic hepatitis B (CHB), to assist in preventing serious liver disease.

It is now known that people who were previously considered to have ‘unresolved hepatitis B virus carrier state’ in fact have CHB. CHB requires lifelong recall and monitoring for disease progression, even when asymptomatic. It is estimated that South Australia has 14,400 people with CHB, 6,600 (46%) who are undiagnosed.  Current clinical guidelines recommend that patients with CHB should be monitored at least annually by their GP for disease progression and suitability for anti-viral treatment.

This video provides clinical advice from the Royal Adelaide Hospital, Viral Hepatitis Centre Co-Directors Dr Edmund Tse (Head of Hepatology) and Dr David Shaw (Head of Infectious Diseases), Margery Milner (Viral Hepatitis CPC) and Dr Sam Elliott, a GP and Hepatitis B s100 Community Prescriber.